MD Anderson-led Phase III trial meets primary endpoint with talazoparib over chemotherapy HOUSTON ― In a randomized, Phase III trial led by researchers at The University of Texas MD Anderson Cancer Center, the PARP inhibitor talazoparib extended progression-free survival (PFS) and improved quality-of-life measures over available chemotherapies for patients with metastatic HER2-negative breast cancer and mutations in the BRCA1/2 genes. The results of the EMBRACA trial were presented today at the 2017 San Antonio Breast Cancer Symposium by Jennifer Litton, M.D., associate […]
